Business Wire

Rivoli Group AG Under New Management

3.7.2017 17:30 | Business Wire

Jaa

Mourad Malloul takes over the management of the Swiss investment group, Rivoli Group AG. He was unanimously appointed president of the Group in a resolution of the general meeting of 3 May 2017. Mourad Malloul, the new president, will be supported by a 14-strong expert team on the administrative board.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170703005363/en/

Mourad Malloul, newly elected president of the Swiss investment group Rivoli Group AG, will be focus ...

Mourad Malloul, newly elected president of the Swiss investment group Rivoli Group AG, will be focusing on growth through innovation-driven project development in the EMEA region (photo: Business Wire)

Malloul, a private equity strategist, has been active in the Group as a senior partner since 2014. During this time, he successfully set up innovation-oriented projects, especially in high-growth emerging and developing countries. In doing so, he largely contributed to profiling the market positioning of the investment group.

While responsible for the Middle East and North Africa (MENA) region, Mourad Malloul built up a wide-reaching network on-site in the key markets for the Rivoli Group. In the future, he will also be personally responsible for the business presence – on a temporary basis at least – in the African markets. With his convincing investment strategy, Malloul has succeeded in winning the long-term trust of investors. At the same time, the new president has ensured that the decision-making process within the Group is clearly optimized and that results can be implemented much quicker.

Malloul agrees with the Group’s investors: venture capital and private equity transactions in the 12 current locations need to be further developed. Furthermore, he wants to invest together with the investors in project development in emerging countries with high growth potential. The declared aim is to develop the Rivoli Group into one of the leading venture capital investors in Europe, with more effective networking in selected developing markets. The second strategic line for Malloul is to extend the competence of the Rivoli Group AG to support SMEs in European capital market transactions and in financing measures independent of the banks.

Company profile:

The Rivoli Group AG is an international consulting and investment company based in Zurich, Switzerland. The company focuses on innovative companies in the seed and early phase, and makes available its equity capital, know-how and networks to its portfolio companies. The service portfolio of the Rivoli Group also includes project developments in emerging countries with above-average growth opportunities.

The Swiss group manages a commutative project volume of around 6.5 billion Swiss francs (approx. 6 billion euros).

The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.

Contact information

RIVOLI GROUP AG
Sarah Mertens, +41 44 388 5459
Fax: +41 44 388 5458
info@rivoli-group.com
www.rivoli-group.com

Tietoja julkaisijasta

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Tilaa tiedotteet sähköpostiisi

Haluatko tietää asioista jo ennen kuin ne uutisoidaan? Kun tilaat tiedotteemme tältä julkaisijalta, saat ne sähköpostiisi yhtä aikaa suomalaisen median kanssa. Tilauksen voit halutessasi perua milloin tahansa.

Lue lisää julkaisijalta Business Wire

Boehringer Ingelheim starts clinical study on interchangeability between its adalimumab biosimilar candidate and HUMIRA®27.7.2017 16:00Tiedote

Boehringer Ingelheim announced today that the first patient has been enrolled into its VOLTAIRE-X interchangeability study. The goal of the study is to demonstrate that BI 695501 is interchangeable with the U.S.-marketed formulation of Humira®* 40mg/0.8mL. This is the first study in the U.S. to investigate an interchangeability designation for an adalimumab biosimilar candidate. The study will compare the pharmacokinetics and clinical outcomes between patients receiving Humira® continuously, versus those who switch repeatedly between Humira® and BI 695501, Boehringer Ingelheim’s adalimumab biosimilar candidate.1 The study will also assess safety, immunogenicity and efficacy.1 “We are pleased that the first patient has now been enrolled in VOLTAIRE-X, and look forward to continued recruitment and patient follow-up,” said Ivan Blanarik, Senior Vice President and Head of

Acxiom Launches Connected Spaces27.7.2017 15:30Tiedote

Today, Acxiom® (Nasdaq: ACXM), in collaboration with Adobe, announced the launch of Connected Spaces, a global solution aimed at delivering more relevant omnichannel experiences to customers. Connected Spaces is designed to revolutionise customer experience and business returns for retail, travel and leisure locations such as airports, malls, sports stadiums, concert arenas and resorts. A pioneering example is Heathrow airport. Heathrow is able to deliver more relevant communications to customers in real-time as part of its overall engagement strategy and is already generating exceptional results including an increase in spend of 20-25 percent for engaged customers. Common to airports, malls and the like is a high footfall of consumers who intend to visit multiple concession, franchise, or subcontracted brands operating in their environments. This can translate to a relative

Watch BizWireTV: Helix Brings DNA Kits to the Public and Michael Kors Gets Ready to Buy Jimmy Choo27.7.2017 15:08Tiedote

On the latest BizWireTV, catch the latest Quick Biz Hits. Also see what’s happening in the startup world with the Accelerator Report, featuring the VC Watch and this week’s Startup Standout. This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170727005456/en/ BizWireTV is hosted by Jordyn Rolling (Photo: Business Wire) Now you can watch BizWireTV, and the latest breakthroughs in tech from the biggest brands, on any screen you want by downloading the new app through the Apple TV and iPhone App Store and Google Play for Android devices. Top of the Wire Helix launches first online consumer marketplace for DNA-powered products that offer insights on ancestry, entertainment, family, fitness, health and nutrition. Watch BizWireTV to

European Commission Grants Orphan Drug Designation to Allena Pharmaceuticals’ Investigational Therapy for the Treatment of Primary Hyperoxaluria27.7.2017 14:05Tiedote

Allena Pharmaceuticals, Inc., a specialty biopharmaceutical company dedicated to bringing first in class, specific, non-absorbed, oral enzyme therapeutics to patients with serious renal, urologic and orphan diseases, announced today that the European Commission has granted orphan drug designation to Allena’s investigational product ALLN-177, Bacillus subtilis oxalate decarboxylase, for the treatment of primary hyperoxaluria (PH). The orphan designation was granted to Allena Pharmaceuticals Ireland Limited, a subsidiary of Allena Pharmaceuticals, Inc. Allena’s lead compound ALLN-177, is being developed to treat patients with severe hyperoxaluria, a condition characterized by markedly elevated urinary oxalate excretion. PH, a type of severe hyperoxaluria, is a rare genetic disorder caused by endogenous overproduction of oxalate by the liver that can result in kidney stone disease, kidney

Subscription Period for Superior Industries’ Tender of UNIWHEELS AG’s Shares to Close Monday, July 31, 201727.7.2017 09:00Tiedote

Superior Industries International, Inc. (NYSE:SUP), one of the world’s largest manufacturers of aluminum wheels, reiterated today that the subscription period for the tender offer to acquire all remaining outstanding shares of UNIWHEELS AG (“UNIWHEELS”) will close Monday, July 31, 2017. On June 30, 2017, Superior announced it had commenced a tender offer to acquire the remaining 954,920 shares held by the public shareholders, which represents approximately 7.7% of the total outstanding shares of UNIWHEELS, for cash consideration of 247.87zl per share. Superior acquired the other approximately 92.3% of the outstanding shares through a tender offer that was settled on May 30, 2017, where the public shareholders also received cash consideration of 247.87zl per share. Following the settlement of the tender offer, Superior will finalize the proceedings to delist UNIWHEELS’ common stock from

Ipsen Delivers Strong Sales Growth of 18.8%1 in the First Half of 2017 and Upgrades Its Guidance for Full Year 201727.7.2017 08:00Tiedote

Regulatory News: Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical group, today announced financial results for the first half of 2017. H1 2017 Highlights Strong operating performance of 18.8%1 Group sales growth and Core Operating Income margin improvement by 1.2 points to 26.2% of sales Specialty Care sales growth of 23.1%1 reflects continued Somatuline® momentum and includes contribution of key new products Cabometyx® and Onivyde® Consumer Healthcare sales growth of 1.3%1 including contribution of newly acquired products Upgraded full year 2017 guidance of Specialty Care sales growth greater than 24.0%1, slight growth1 of Consumer Healthcare sales, and Core Operating Income margin greater than 25.0% o

Uutishuoneessa voit lukea tiedotteitamme ja muuta julkaisemaamme materiaalia. Löydät sieltä niin yhteyshenkilöidemme tiedot kuin vapaasti julkaistavissa olevia kuvia ja videoita. Uutishuoneessa voit nähdä myös sosiaalisen median sisältöjä. Kaikki STT Infossa julkaistu materiaali on vapaasti median käytettävissä.

Tutustu uutishuoneeseemme